The beta lactam antibiotics as an empirical therapy in a developing country: An update on their current status and recommendations to counter the resistance against them

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 6, 2013, Pages 1207-1214

  Thakuria, Bhaskar ^a   Lahon, Kingshuk ^b  

^a SUBHARTI MEDICAL COLLEGE   (India)

^b MAHATMA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

AmpC; Beta lactams; Empirical use; ESBL; HLAR; MBL; MRSA; Resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; CEFTOBIPROLE; CEPHALOSPORIN; CEPHAMYCIN DERIVATIVE; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; LINEZOLID; POLYMYXIN B; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CARBUNCLE; CLINICAL PRACTICE; COMMUNITY ACQUIRED INFECTION; DEVELOPING COUNTRY; DRUG EFFICACY; EAR INFECTION; EMPIRICAL RESEARCH; ENTEROBACTER; ENZYME SYNTHESIS; ESCHERICHIA COLI; EYE INFECTION; FURUNCULOSIS; GEOGRAPHY; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HEALTH CARE FACILITY; HOSPITAL INFECTION; HUMAN; HYDROLYSIS; INDIA; INFECTION; KLEBSIELLA; LABORATORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL GROWTH; MORAXELLA CATARRHALIS; NEISSERIA GONORRHOEAE; PRESCRIPTION; PREVALENCE; PSEUDOMONAS; RESPIRATORY TRACT INFECTION; REVIEW; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STUDENT ATTITUDE; TREATMENT INDICATION; UNDERGRADUATE STUDENT; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84878847048     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5239.3052     Document Type: Review

References (89)

1. Neushal P. Science, Government and the Mass Production of Penicillin. J Hist Med Allied Sci. 1993;48(4):371-95.
2. Chandel AK, Rao M L V, Narasu L, Singh OV. The realm of penicillin G acylase in β-lactam antibiotics. Enzyme and Microbial Technology 2008;42(3):199-207
3. Directorate general of Health Services. Ministry of Health and Family Welfare, Government of India. National policy for containment ofantimicrobial resistance India. DGHS, New Delhi, 2011.
4. Rivera SM, Gilman AG. Drug invention and the pharmaceutical industry. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's The Pharmacological basis of Therapeutics. 12th edition. USA: McGraw Hill, 2011;3-16.
5. Beta lactam antibiotics. In: Tripathi KD, editor. Essentials of Medical Pharmacology. 6th edition. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2008:694-709.
6. Penicillins, cephalosporins and other beta lactam antibiotics. In: Sharma HL, Sharma KK, editors. Principles of Pharmacology. 2nd edition. New Delhi: Paras Medical Publishers, 2011;723-24.
7. Utsui Y, Yokota T. Role of an altered penicillin binding protein in methicillin-and cephem resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;28:397-403.
8. Banerjee R, Gretes M, Li Basuino, Strynadka N, Chambers HF. In Vitro Selection and Characterization of Ceftobiprole-Resistant Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(6):2089-96.
9. Rizvi MW, Shujatullah F, Malik A, Khan HM. Ceftobiprole-A novel cephalosporin to combat MRSA. East J Med. 2011;16:1-8.
10. Centers for Disease Control and Prevention. MRSA infections-MRSA Surveillance. Atlanta: CDC, 2011.
11. Majumder D, Bordoloi JS, Phukan AC, Mahanta J. Antimicrobial susceptibility pattern among methicillin resistant staphylococcus isolates in Assam. Indian J Med Microbiol. 2001;19:138-40.
12. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis. 2006;6:156.
13. Arora S, Devi P, Arora U, Devi B. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in a tertiary care hospital in Northern India. J Lab Physicians. 2010;2:78-81.
14. Pathogen regulation directorate, Public health agency of Canada. Enterococcus faecalis pathogen safety data sheet-infectious substances. Canada: PHAC, 2010.
15. Wayne, PA. Performance Standards for Antimicrobial Susceptibility Testing; 17th informational supplement, CLSI M2-A9. Clinical and Laboratory Standards Institute.
16. Agarwal VA, Jain YI, Pathak AA. Concomitant high level resistance to penicillin and aminoglycosides in Enterococci at Nagpur, Central India. Indian J Med Microbiol. 1999; 17:85-87.
17. Randhawa RS, Kapoor L, Singh V, Mehta G. Aminoglycoside resistance in enterococci isolated from paediatric septicaemia in a tertiary care hospital in north India. Indian J Med Res. 2004;199:(Suppl) 77-9.
18. Adhikari L. High-level aminoglycoside resistance and reduced sus-ceptibility to vancomycin in nosocomial enterococci. J Global Infect Dis. 2010;2:231-35.
19. Narayanaswamy A, Rajalakshmi K, Varadharajan M. Speciation and antimicrobial susceptibility pattern of Enterococci from a tertiary health care center of south India. J Pharm Res. 2011;4(4):989-90.
20. Center for disease dynamics economics and policy. Resistance map. Vancomycin-resistant enterococcus. Available from http://cddep.org/ResistanceMap/bug-drug/VRE Last accessed Aug 6, 2012.
21. Ghoshal U, Garg A, Tiwari DP, Ayyagiri A. Emerging vancomycin resistance in Enterococci in India. Indian J Pathol Microbiol. 2006; 49(4):620-22.
22. Taneja N, Rani P, Emmanuel R, Sharma M. Significance of vancomycin resistant enterococci from urinary specimens at a tertiary care centre in northern India. Indian J Med Res. 2004;119:72-74.
23. Kapoor L, Randhawa VS, Deb M. Antimicrobial resistance of enterococcal blood isolates at a pediatric care hospital in India. Jpn J Infect Dis. 2005;58:101-03.
24. Shah L, Mulla S, Patel KG, Rewadiwala S. Prevalence of enterococci with higher resistance level in a tertiary care hospital: a matter of concern. National Journal of Medical Research. 2012;2(1):25-27.
25. Karmarkar MG, Gershom ES, Mehta PR. Enterococcal infections with special reference to phenotypic characterization and drug resistance. Indian J Med Res. 2004; 119:22-25.
26. Dhillon RHP, Clark J. ESBLs: A clear and present danger Crit Care Res Pract 2012;2012 Article ID 625170doi:10.1155/2012/625170.
27. Bhattacharya S. ESBL-From petri dish to the patient. Indian J Med Microbiol. 2006;24(1):20-24.
28. Kumar M, Lakshmi V, Rajagopalan R. Occurrence of extended spec-trum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol. 2006;24(3):208-11.
29. Tsering D, Das S, Adhikari L, Pal R, Singh T. Extended spectrum beta-lactamase detection in gram-negative bacilli of nosocomial origin. J Glob Infect Dis. 2009;1(2):87-92
30. Varaiya A, Dogra J, Kulkarni M, Bhalekar P. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections. Indian J Pathol Microbiol. 2008;51(3):370-72.
31. Agrawal P, Ghosh A, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum β-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol. 2008;51(1):139-42.
32. Babypadmini S, Appalaraju B. Extended spectrum-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol. 2004;22(3):172-74.
33. Wani KA, Thakur MA, Fayaz AS, Fomdia B, Gulnaz B, Maroof P. Extended Spectrum-Lactamase Mediated Resistance in Escherichia Coli in a Tertiary Care Hospital. Int J Health Sci. 2009;3(2):155-63.
34. Manchanda V, Singh NP. Occurrence and detection of AmpC {beta}-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother. 2003;51(2):415-18.
35. Goyal A, Prasad K, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res. 2009;129(6):695-700.
36. Gupta V. Detection of ESBLs using third and fourth generation cephalos-porins in double disc synergy test. Indian J Med Res. 2007;126:486-87.
37. Jain A, Mondal R. Detection of extended spectrum beta-lactamase production in clinical isolates of Klebsiella spp. Indian J Med Res. 2008;127(4):344-46.
38. Sridhar Rao P, Basavarajappa K, Krishna G. Detection of extended spectrum beta-lactamase from clinical isolates in Davangere. Indian J Pathol Microbiol. 2008;51(4):497-99.
39. Bhattacharjee A, Sen M, Prakash P, Gaur A, Anupurba S, Nath G. Observation on integron carriage among clinical isolates of Klebsiella pneumoniae producing extended-spectrum β-lactamases. Indian J Med Microbiol. 2010;28(3):207-10.
40. Papanicolaou GA, Medeiros AA, Jacoby GA Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino-and alpha-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990;34:2200-09.
41. Coudron PE, Moland ES, Thomson KS. Occurrence and Detection of AmpC Beta-Lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center. J Clin Microbiol. 2000;38(5):1791-96.
42. Li Y, Li Q, Du Y, Jiang X, Tang J, Wang J, et al. Prevalence of Plasmid-Mediated AmpC β-Lactamases in a Chinese University Hospital from 2003 to 2005: First Report of CMY-2-Type AmpC β-Lactamase Resistance in China. J Clin Microbiol. 2008;46(4):1317-21.
43. Song W, Kim J, Bae IK, Jeong SH, Seo YH, Shin JH, et al. Chromosome-Encoded AmpC and CTX-M Extended-Spectrum β-Lactamases in Clinical Isolates of Proteus mirabilis from Korea. Antimicrob Agents Chemother 2011;55(4):1414-19.
44. Song W, Kim JS, Kim HS, Yong D, Jeong SH, Park MJ, et al. Increasing trend in the prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis. 2006;55:219-24.
45. Lee K, Lee M, Shin JH, Lee MH, Kang SH, Park AJ, et al. Prevalence of plasmid-mediated AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae in Korea. Microb Drug Resist. 2006;12(1):44-49.
46. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009; 22(1):161-82.
47. Ratna AK, Menon I, Kapur I, Kulkarni R. Occurrence and detection of AmpC beta-lactamases at a referral hospital in Karnataka. Ind J Med Res. 2003;118:29-32.
48. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R, et al. Evaluation of methods for AmpC beta lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol. 2005;23(2):120-24.
49. Shahid M, Malik A, Akram M, Agrawal LM, Khan AU, Agrawal M. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance. Int J Inf Dis. 2008;12:256-64.
50. Ananthan S, Subha A. Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli. Indian J Med Microbiol. 2005;23(1):20-23.
51. Rajni E, Rawat U, Malhotra VL, Mehta G. Occurrence and detection of AmpC beta lactamases among clinical isolates of E. coli and K. pneumoniae causing UTI. J Commun Dis. 2008;40(1):21-25.
52. Subha A, Devi VR, Ananthan S. AmpC beta-lactamase producing multidrug resistant strains of Klebsiella spp. & Escherichia coli isolated from children under five in Chennai. Indian J Med Res. 2003; 117:13-18.
53. Khan MKR, Thukral SS, Gaind R. Evaluation of a modified double disc synergy test for detection of extended spectrum β-lactamases in AmpC β-lactamase producing Proteus mirabilis. Indian J Med Microbiol. 2008;26(1):58-61.
54. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997;41(2):223-32
55. Livermore DM. Carbapenemases. J Antimicrob Chemother 1992; 29:609-13.
56. Livermore D M. Carbapenemases: the next generation of β-lactamases ASM News. 1993; 59:129-35.
57. Payne D J. Metallo-β-lactamases-a new therapeutic challenge. J Med Microbiol. 1993;39:93-99.
58. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17(10):1791-8. Available from http://www.cdc.gov/eid/article/17/10/11-0655_article.htm. Last accessed Aug 28, 2012.
59. Kallen A, Guh A. United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae. Euro Surveill. 2012;17(26):pii=20207. Available online: http://www.eurosurveillance.org/ViewArticle.aspx ArticleId=20207.
60. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev. 2007; 20:440-58.
61. Centers for Disease Control and Prevention. Detection of Entero-bacteriaceae isolates carrying metallo-beta-lactamase. MMWR Morb Mortal Wkly Rep. 2010; 59:750.
62. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010;15(46):pii=19711. Available at: http://www.eurosurveillance.org/ViewArticle.aspx ArticleId=19711 Last accessed 18 Aug 2012.
63. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29:996-1011.
64. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-b-lactamase gene, bla NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53:5046-54.
65. Moellering RC Jr. NDM-1-a cause for worldwide concern. N Engl J Med. 2010; 363: 2377-79.
66. Struelens MJ, Monnet DL, Magiorakos AP, O'Connor FS, Giesecke J. New Delhi metallobeta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010; 15: pii: 19716. Available at: http://www.eurosurveillance.org/ViewArticle.aspx ArticleId=19716 Last accessed 18 Aug 2012.
67. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
68. Taneja N, Aharwal S.M, Sharma M. Imipenem Resistance in non fermenters causing nosocomial urinary tract infection. Indian J Med Sci. 2003;57:294-99.
69. Navneeth BV, Sridaran D, Sahay D, Belwadi M. A preliminary study on Metallo beta lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res. 2002;116:264-67.
70. Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J Pathol Microbiol. 2008;51:200-03.
71. Jesudason MV, Kandathil AJ, Balaji V. Comparison of two methods to detect carbapenemase and metallo-β-lactamase production in clinical isolates. Indian J Med Res. 2005;121:780-83.
72. Sarkar B, Biswas D, Prasad R, Sharma JP. A clinical microbiological study on the importance of Pseudomonas in nosocomially infected ICU patients, with special reference to metallo β-lactamase production. Indian J Patho Microbiol. 2006;49:44-48.
73. Sarma JB, Bhattacharya PK, Kalita D, Rajbangshi M. Multidrug-resistant Enterobacteriaceae including metallo-β-lactamase producers are predominant pathogens of healthcare-associated infections in an Indian teaching hospital. Indian J Med Microbiol. 2011; 29(1):22-27.
74. Rizvi M, Fatima N, Rashid M, Shukla I, Malik A, Usman A, et al. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay. J Infect Dev Ctries. 2009;3(4):285-94.
75. Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB, Patwardhan NS. Metallo-β-lactamase-producing clinical isolates from patients of a tertiary care hospital. J Lab Physicians. 2011;3(2):93-97.
76. Rai S, Manchanda V, Singh NP, Kaur IR. Zinc-dependent carbapenemases in clinical isolates of family Enterobacteriaceae. Indian J Med Microbiol 2011;29(3):275-79.
77. Livermore DM. Mechanisms of resistance to β-lactam antibiotics. Scand J Infect Dis. 1991;Suppl 78:7-16.
78. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9 doi:10.1093/jac/dki166 Available from http://jac.oxfordjournkals.org/content/56/1/52.short. Last accessed Aug 13, 2012.
79. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-Associated Diarrhea: Epidemiological Data from Western Australia Associated with a Modified Antibiotic Policy. Clin Infect Dis. 2002;35(12):1457-62.
80. O'Connor KA, Kingston M, O'Donovan M, Cryan B, Twomey C, O'Mahoney D. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJ Med. 2004;97:423-29.
81. Petri WA, Jr. Penicillins, cephalosprins and other β-lactam antibiotics. In: Brunton L, Chabner B, Knollman B., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. USA: McGraw Hill; 2011. p.1499.
82. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother. 2001;48:463-78.
83. Gould IM. Control of antibiotic use in the United Kingdom. J Antimicrob Chemother. 1988;22:395-401.
84. Health Protection agency Department of Health Advisory committee on Health associated infection (ARHAI). Advice on Carbapenemase Producers: Recognition, infection control and treatment. HPA, UK, 2012. Available from http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1294740725984 Last accessed Aug 30, 2012.
85. Livermore D. Epidemiology of antibiotic resistance. Intensive Care Medicine 2000;26:Suppl1 S14-21.
86. WHO. Drug resistance. WHONET software. WHO, Geneva, 2012. Available from http://www.who.int/drugresistance/whonetsoftware/en/. Last accessed Oct 27, 2012.
87. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
88. MontalbAin-Lapez M, Sainchez-Hidalgo M, Valdivia E, MartAnez-Bueno M, Maqueda M. Are bacteriocins underexploited Novel applications for old antimicrobials. Curr Pharm Biotechnol. 2011; 12(8):1205-20.
89. Inal JM. Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp. (Warsz) 2003;51(4):237-44.